2023 Has been a busy year for JAMA Oncology and its editors. We have had the pleasure of receiving a substantial number of submissions and reviewing an exciting array of scientific studies, opinions, and reviews. The use of artificial intelligence to bolster the oncology workforce was one of our most popular topics, but the verdict is still out on whether a chatbot can ace the medical, surgical, or radiation oncology board examinations. We continued to learn more this year about the role of physical activity in preventing cancer recurrence and even in preventing multiple different types of cancer. Although several studies have evaluated different intensities of activity, we still do not have an exact number to write on a physical activity prescription for each patient. We just know that we should probably give a physical activity prescription to each patient. We have reported results from several large phase 3 randomized clinical trials affecting standard of care, as well as exciting and promising results from smaller phase 1 and 2 studies with outstanding correlative science. And JAMA Oncology continues to publish important studies reporting the global health impact of cancer. We hope that you enjoyed reading these articles as much as we enjoyed choosing them for publication.
Risultati per: Linee-guida GOLD 2023,cosa cambia?
Questo è quello che abbiamo trovato per te
JAMA Psychiatry Peer Reviewers in 2023
We sincerely thank the 659 peer reviewers who completed manuscript reviews for JAMA Psychiatry in 2023.
JAMA Dermatology —The Year in Review, 2023
2023 Was another exceptional year for JAMA Dermatology. The editorial team evaluated a steady number of article submissions (Table). A total of 956 of 2756 submissions were research articles. Acceptance rates remained stable, with 10% of submissions overall and 11% of research articles accepted for publication. The journal continued to maintain its goal of reducing the time to publication, keeping the median days of acceptance to publication to 63 days while offering timely editorial decisions, including maintaining the median time to first decision without peer review to 4 days. The median time of receipt to first decision with peer review increased slightly to 63 days, highlighting an area for process improvement aligned with our commitment to publishing excellence. JAMA Dermatology’s Journal Impact Factor remained high at 10.9.
ACP: linee guida cliniche per i nuovi trattamenti del diabete tipo 2
Morbillo, in Europa i casi sono saliti di 60 volte tra il 2022 e il 2023
1,8 milioni di bambini non vaccinati negli ultimi tre anni
Nel 2023 18 milioni accessi a Pronto soccorso, 4 milioni impropri
Agenas, +6% sul 2022. Il 68% Codici bianchi e verdi
Sifting for Gold in Terabytes of Data: Illuminating Cardiovascular Biology in the ‘Omics Age
Circulation, Volume 149, Issue 17, Page 1323-1325, April 23, 2024.
NICE: linee guida sulla diagnosi e gestione dell’endometriosi
NCCN: linee guida aggiornate sul cancro alla prostata
Linee guida di consenso per la gestione delle metastasi peritoneali
Gastroenterology/Hepatology: What You May Have Missed in 2023
Annals of Internal Medicine, Ahead of Print.
What You May Have Missed in 2023: Keeping Up With the Constant Flow of New Medical Evidence
Annals of Internal Medicine, Ahead of Print.
Pulmonology: What You May Have Missed in 2023
Annals of Internal Medicine, Ahead of Print.
Critical Care: What You May Have Missed in 2023
Annals of Internal Medicine, Ahead of Print.
Cardiology: What You May Have Missed in 2023
Annals of Internal Medicine, Ahead of Print.
Oncology: What You May Have Missed in 2023
Annals of Internal Medicine, Ahead of Print.